Clinical Barriers to Effective Pharmacotherapy in Co-occurring Psychiatric and Substance Use Disorders

被引:3
作者
Malat, Jan [1 ,2 ]
Kahn, David A. [3 ]
机构
[1] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A1, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada
[3] Columbia Univ Coll Phys & Surg, New York, NY 10027 USA
关键词
pharmacotherapy; addiction; psychopharmacology; prescribing; comorbidity; NATIONAL EPIDEMIOLOGIC SURVEY; PSYCHOTROPIC MEDICATION; ALCOHOL; PSYCHOTHERAPY; DEPENDENCE; ANXIETY; PERSPECTIVE; MANAGEMENT; OBJECT; ABUSE;
D O I
10.1097/01.pra.0000405367.82419.29
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Prescribing medications to patients with co-occurring psychiatric and substance use disorders often evokes distressing emotional responses from both clinician and patient that affect the delivery of appropriate pharmacological treatment. One important polarization revolves around the clinician under-prescribing to avoid feeling like he or she is overmedicating the patient versus over-prescribing when risk levels are minimized. A case report illustrates some common, rapidly shifting responses to both medication and clinician. These reactions include 1) an idealized, passive relation to the medication followed by disappointment in its weakness, 2) minimizing the danger of medication through idiosyncratic and potentially dangerous overuse to replicate effects of the addictive substance, or 3) experiencing the medication as harmful, leading to phobic avoidance and underutilization. The recommended clinical response is to avoid these polarizations and to engage with the patient's suffering and dangerous behavior by 1) taking reasonable pharmacological risks, 2) establishing provisions for safe use and frequent monitoring, 3) conveying tolerance for idiosyncratic use within safe limits, 4) regular exploration of the meaning of the medication with links to both the addiction history and the treatment relationship, and 5) frequent psychoeducation. (Journal of Psychiatric Practice 2011;17:360-367)
引用
收藏
页码:360 / 367
页数:8
相关论文
共 42 条
[11]   The fate of integrated treatment: Whatever happened to the biopsychosocial psychiatrist? [J].
Gabbard, GO ;
Kay, J .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (12) :1956-1963
[12]  
GLOVER E, 1932, INT J PSYCHOANAL, V53, P63
[13]   Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders - Results from the national epidemiologic survey on alcohol and related conditions [J].
Grant, BF ;
Stinson, FS ;
Dawson, DA ;
Chou, SP ;
Dufour, MC ;
Compton, W ;
Pickering, RP ;
Kaplan, K .
ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (08) :807-816
[14]   Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the united states - Results from the national epidemiologic survey on alcohol and related conditions [J].
Grant, BF ;
Stinson, FS ;
Dawson, DA ;
Chou, SP ;
Ruan, J ;
Pickering, RP .
ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (04) :361-368
[15]  
GUTHEIL TG, 1982, B MENNINGER CLIN, V46, P321
[16]   MEDICATION CONSULTATION AND SPLIT TREATMENT DURING PSYCHOTHERAPY [J].
KAHN, DA .
JOURNAL OF THE AMERICAN ACADEMY OF PSYCHOANALYSIS, 1991, 19 (01) :84-98
[17]   The self-medication hypothesis of substance use disorders: A reconsideration and recent applications [J].
Khantzian, EJ .
HARVARD REVIEW OF PSYCHIATRY, 1997, 4 (05) :231-244
[18]   A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co-morbid substance use disorders [J].
Kollins, Scott H. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) :1345-1357
[19]   ADHD, Substance Use Disorders, and Psychostimulant Treatment Current Literature and Treatment Guidelines [J].
Kollins, Scott H. .
JOURNAL OF ATTENTION DISORDERS, 2008, 12 (02) :115-125
[20]  
Kramer PeterD., 1993, LISTENING PROZAC PSY